4q loss is potentially an important genetic event in MM tumorigenesis: identification of a tumor suppressor gene regulated by promoter methylation at 4q13.3, platelet factor 4.

In this study, we have elucidated the chromosomal imbalances in the multistep pathogenesis and delineated several critical tumor suppressor gene (TSG) loci in multiple myeloma (MM). By using comparative genomic hybridization, allelotyping, and multicolor interphase fluorescence in situ hybridization, 5 MM cell lines and bone marrow CD138+ plasma cells from 88 Chinese patients with monoclonal gammopathy of undetermined significance (MGUS) and early and advanced stages of MM were investigated. In all MGUS and MM samples, chromosome copy number abnormalities were detected. A higher number of chromosomal imbalances and specific genetic alterations are involved in MGUS to MM transition (-6q, +3p, and +1p) and MM progression (+2p and +9q). In addition to -13q, we first found high frequencies (42% to 46%) of -4q involving high percentages (70% to 74%) of clonal plasma cells in both MGUS and MM, suggesting that inactivation of TSG in this region is also a potentially critical genetic event in MM tumorigenesis. By high-resolution allelotyping, we defined a common deletion region on 4q13.3 and found that a candidate TSG, platelet factor 4, was frequently silenced by promoter hypermethylation in MM (15 of 28) and MM cell lines (5 of 5). These data have opened up a new approach in the molecular targeting therapy and provide novel insights into MM tumorigenesis.

[1]  K. Yamaguchi,et al.  Platelet factor 4 gene transfection into tumor cells inhibits angiogenesis, tumor growth and metastasis. , 2005, Anticancer research.

[2]  A. Bikfalvi Platelet factor 4: an inhibitor of angiogenesis. , 2004, Seminars in thrombosis and hemostasis.

[3]  R. Bataille,et al.  Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report , 2004 .

[4]  Gonzalez,et al.  Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. , 2003, Blood.

[5]  E. Zabarovsky,et al.  Distinct organization of the candidate tumor suppressor gene RFP2 in human and mouse: multiple mRNA isoforms in both species- and human-specific antisense transcript RFP2OS. , 2003, Gene.

[6]  Alfonso Bellacosa,et al.  Genetic hits and mutation rate in colorectal tumorigenesis: Versatility of Knudson's theory and implications for cancer prevention , 2003, Genes, chromosomes & cancer.

[7]  Sun-Hwa Park,et al.  Detection of genetic alterations in Korean ovarian carcinomas by degenerate oligonucleotide primed polymerase chain reaction-comparative genomic hybridization. , 2003, Cancer genetics and cytogenetics.

[8]  S. Lakhani,et al.  The diagnosis and management of pre-invasive breast disease: Genetic alterations in pre-invasive lesions , 2003, Breast Cancer Research.

[9]  Yixin Jin,et al.  Suppression of tumor growth by viral vector-mediated gene transfer of N-terminal truncated platelet factor 4. , 2003, Cancer biotherapy & radiopharmaceuticals.

[10]  T. Manshouri,et al.  Use of plasma DNA in detection of loss of heterozygosity in patients with multiple myeloma , 2003, European journal of haematology.

[11]  Kenneth C. Anderson,et al.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.

[12]  T. T. Lau,et al.  Chromosomal aberrations of multiple myeloma in Chinese patients at diagnosis: a study by combined G-banding and multicolor spectral karyotyping. , 2003, Oncology reports.

[13]  Martins Marta,et al.  Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia , 2003, Cancer.

[14]  D. Catovsky,et al.  Delineation of the minimal region of loss at 13q14 in multiple myeloma , 2003, Genes, chromosomes & cancer.

[15]  M. Schrappe,et al.  Long-term study of the clinical significance of loss of heterozygosity in childhood acute lymphoblastic leukemia , 2003, Leukemia.

[16]  A. Órfão,et al.  Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia. , 2003, Cancer.

[17]  K. Choy,et al.  Loss of heterozygosity and mutations are the major mechanisms of RB1 gene inactivation in Chinese with sporadic retinoblastoma , 2002, Human mutation.

[18]  S. Ma,et al.  Novel O6‐methylguanine‐DNA methyltransferase SNPs: A frequency comparison of patients with familial melanoma and healthy individuals in Sweden , 2002, Human mutation.

[19]  G. Ahmann,et al.  Genomic abnormalities in monoclonal gammopathy of undetermined significance. , 2002, Blood.

[20]  S. K. Kim,et al.  Identification of Tumor Suppressor Loci on the Long Arm of Chromosome 4 in Primary Small Cell Lung Cancers , 2002 .

[21]  John Crowley,et al.  Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. , 2002, Blood.

[22]  J. Zucman‐Rossi,et al.  Specific association between alcohol intake, high grade of differentiation and 4q34-q35 deletions in hepatocellular carcinomas identified by high resolution allelotyping , 2002, Oncogene.

[23]  D. Harrington,et al.  Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study. , 2002, Cancer research.

[24]  S. K. Kim,et al.  Identification of tumor suppressor loci on the long arm of chromosome 4 in primary small cell lung cancers. , 2000, Yonsei medical journal.

[25]  S. Casas,et al.  Interstitial deletions at the long arm of chromosome 13 may be as common as monosomies in multiple myeloma. A genotypic study. , 2002, Haematologica.

[26]  U. Jäger,et al.  Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance , 2000, Leukemia.

[27]  R. Bataille,et al.  Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myélome. , 1999, Blood.

[28]  R. Bataille,et al.  14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome. , 1999, Cancer research.

[29]  O. Cussenot,et al.  Loss of heterozygosity at chromosome arm 13q and RB1 status in human prostate cancer. , 1999, Human pathology.

[30]  G. Capellá,et al.  Tracking recurrent quantitative genomic alterations in colorectal cancer: allelic losses in chromosome 4 correlate with tumor aggressiveness. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[31]  A. Stewart,et al.  Frequent monoallelic loss of D13S319 in multiple myeloma patients shown by interphase fluorescence in situ hybridization , 1999, Leukemia.

[32]  P. L. Bergsagel,et al.  Multiple myeloma: increasing evidence for a multistep transformation process. , 1998, Blood.

[33]  M. Pallavicini,et al.  Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization , 1997, Genes, chromosomes & cancer.

[34]  R. Bataille,et al.  The retinoblastoma susceptibility gene RB-1 in multiple myeloma. , 1997, Leukemia & lymphoma.

[35]  B. Barlogie,et al.  Cytogenetic findings in 200 patients with multiple myeloma. , 1995, Cancer genetics and cytogenetics.

[36]  R. Hruban,et al.  Infrequent inactivation of the retinoblastoma gene despite frequent loss of chromosome 13q in head and neck squamous cell carcinoma. , 1994, Cancer research.

[37]  L. Hawthorn,et al.  Frequent homozygous deletions of the D13S25 locus in chromosome region 13q14 defines the location of a gene critical in leukaemogenesis in chronic B-cell lymphocytic leukaemia. , 1994, Oncogene.

[38]  S. Salmon,et al.  A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.